Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Urofollitropin
Drug ID BADD_D02319
Description Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
Indications and Usage For treatment of female infertility
Marketing Status approved; vet_approved
ATC Code G03GA04
DrugBank ID DB00094
KEGG ID D06269
MeSH ID D050477
PubChem ID 62819
TTD Drug ID D02SBQ
NDC Product Code 76403-5002; 71052-066; 76403-5001
UNII W9BB98U6HP
Synonyms Urofollitropin | Follicle-Stimulating Hormone, Human Urine | Follicle Stimulating Hormone, Human Urine | Human FSH, Urinary | Urinary Human FSH | Fertinex | Metrodin | Neo Fertinorm | Metrodin HP | Metrodin High Purity | High Purity, Metrodin | Bravelle | Follitrin
Chemical Information
Molecular Formula C42H65N11O12S2
CAS Registry Number 26995-91-5
SMILES CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3C CCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematoma24.07.01.001--
Haemoglobin13.01.05.018--Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.001--
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhoids24.10.02.002; 07.15.03.001--
Hallucination, visual19.10.04.007--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
Herpes zoster11.05.02.003; 23.11.05.005; 17.09.03.026--
Hydrocephalus17.07.01.001--
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site induration12.07.03.007; 08.02.03.007--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages